ArticleInternal medicine (Tokyo, Japan)2021

Sofosbuvir/Velpatasvir Plus Ribavirin Combination Therapy for Patients with Hepatitis C Virus Genotype 1a, 2a, or 3b after Glecaprevir/Pibrentasvir Therapy Failed.

Ayami Nonomura et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.